Brainstorm Cell Rg

Brainstorm Cell Therapeutics develops autologous MSC‑based neurodegenerative disease therapies via its NurOwn platform, having completed Phase‑IIIb ALS and Phase‑II MS trials, positioning for a growing neurodegeneration market.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 23
HQ: New York

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
BCLI	Brainstorm Cell Rg Cap: 0.0B	EQUITY	NMS	USD	US10501E2019	Active	📈